Menu

Javascript is not activated in your browser. This website needs javascript activated to work properly.
You are here

Oxidized LDL antibodies in treatment and risk assessment of atherosclerosis and associated cardiovascular disease.

Author:
  • Jan Nilsson
  • Gunilla Nordin Fredrikson
  • Alexandru Schiopu
  • Prediman K Shah
  • Bo Jansson
  • Roland Carlsson
Publishing year: 2007
Language: English
Pages: 1021-1030
Publication/Series: Current Pharmaceutical Design
Volume: 13
Issue: 10
Document type: Journal article review
Publisher: Bentham Science Publishers

Abstract english

Immune responses against oxidized forms of LDL play a critical role in activation and regulation of the inflammatory process that characterizes all stages of atherosclerosis. In humans oxidized LDL is targeted by both IgM and IgG autoantibodies. Immunization of hypercholesterolemic animals with oxidized LDL has been shown to inhibit atherosclerosis demonstrating that at least some of these immune responses have a protective effect. The identification of the structures in oxidized LDL that are responsible for activation of immunity has made it possible to develop novel therapeutic approaches for treatment of atherosclerosis based on active (vaccines) and passive (antibodies) immunization. Studies performed in atherosclerosis-prone mice demonstrate that both peptide-based vaccines and recombinant IgG targeting epitopes in oxidized LDL significantly reduce atherosclerosis. There is also evidence antibodies against oxidized LDL could also be used for imaging atherosclerosis.

Keywords

  • Clinical Medicine

Other

Published
  • Cardiovascular Research - Immunity and Athersosclerosis
  • ISSN: 1381-6128
E-mail: jan [dot] nilsson [at] med [dot] lu [dot] se

Lund University Diabetes Centre, CRC, SUS Malmö, Jan Waldenströms gata 35, House 91:12. SE-214 28 Malmö. Telephone: +46 40 39 10 00